characterizing the immune microenvironment before and following anti-her2 neoadjuvant therapy
Published 4 years ago • 72 plays • Length 7:15Download video MP4
Download video MP3
Similar videos
-
22:27
tumor-immune microenvironment during neoadjuvant targeted therapy in her2-positive breast cancer
-
2:49
her2-e pcr with anti-her2-based neoadjuvant therapies
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
1:29
the predictive value of treatment response after neoadjuvant therapy
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
3:44
alternate: neoadjuvant endocrine treatment in er /her2- breast cancer
-
22:50
neoadjuvant therapy for her2-positive breast cancer - dr. scott christensen
-
0:55
neoadjuvant treatment approach for her2 positive breast cancer
-
3:11
st. gallen consensus 2021: neoadjuvant and adjuvant therapy for her2 breast cancer
-
3:01
alternate: neoadjuvant chemotherapy in er her2- breast cancer
-
0:47
dr. yee on neoadjuvant pertuzumab in her2-positive breast cancer
-
16:58
assessing immune biomarkers of response to anthracyclines in breast cancer
-
1:56
optimizing adjuvant treatment in hr /her2- early breast cancer
-
3:20
dr. hurvitz on eliminating anthracyclines in her2 breast cancer treatment
-
1:25
dr. tolaney on the neoadjuvant therapy for her2-positive breast cancer
-
1:11
an unanswerable question? adjuvant and neoadjuvant treatment of breast cancer
-
1:28
dual her2 blockade in patients with her2-positive breast cancer after pcr
-
3:52
immunotherapy in the neoadjuvant management of her2-positive breast cancer
-
10:05
exploring neoadjuvant therapy for breast cancer: what you need to know